Person:
Huang, Jinghe

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Huang

First Name

Jinghe

Name

Huang, Jinghe

Filters

20091

Settings

Author's Publications: search.filters.isAuthorOfPublication.95d738a9-ef99-45db-be81-63a02bc15379

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    HLA-B*35-Px–mediated Acceleration of HIV-1 Infection by Increased Inhibitory Immunoregulatory Impulses
    (The Rockefeller University Press, 2009) Goedert, James J.; Sundberg, Eric J.; Cung, Thai Duong Hong; Burke, Patrick S.; Preiss, Liliana; Lifson, Jeffrey; Carrington, Mary; Huang, Jinghe; Martin, Maureen P.; Lichterfeld, Mathias; Yu, Xu
    A subset of HLA-B*35 alleles, B*35-Px, are strongly associated with accelerated HIV-1 disease progression for reasons that are not understood. Interestingly, the alternative set of B*35 subtypes, B*35-PY, have no detectable impact on HIV-1 disease outcomes, even though they can present identical HIV-1 epitopes as B*35-Px molecules. Thus, the differential impact of these alleles on HIV-1 disease progression may be unrelated to interactions with HIV-1–specific CD8+ T cells. Here, we show that the B*35-Px molecule B*3503 binds with greater affinity to immunoglobulin-like transcript 4 (ILT4), an inhibitory MHC class I receptor expressed on dendritic cells, than does the B*35-PY molecule B*3501, even though these two B*35 molecules differ by only one amino acid and present identical HIV-1 epitopes. The preferential recognition of B*3503 by ILT4 was associated with significantly stronger dendritic cell dysfunction in in vitro functional assays. Moreover, HIV-1–infected carriers of B*3503 had poor dendritic cell functional properties in ex vivo assessments when compared with carriers of the B*3501 allele. Differential interactions between HLA class I allele subtypes and immunoregulatory MHC class I receptors on dendritic cells thus provide a novel perspective for the understanding of MHC class I associations with HIV-1 disease progression and for the manipulation of host immunity against HIV-1.